GSK’s Shot Against Lung Virus Protects For Two Seasons
- Shot for older adults has efficacy of 67.2% over two seasons
- Longer period of effectiveness may give GSK market advantage
An electron micrograph of the respiratory syncytial virus.
Source: BSIP/UIG/Getty Images
This article is for subscribers only.
GSK Plc’s newly authorized vaccine against respiratory syncytial virus provides protection across two seasons, potentially giving the UK drugmaker an edge over rivals.
The shot for older adults, which was cleared by US regulators in May, demonstrated cumulative efficacy of 67.2% over two winters against the virus in follow-up data from the company’s trials, GSK said in a statement Wednesday.